MacroGenics presents Phase 2 data of vobramitamab duocarmazine in mCRPC at ESMO Congress.

From GlobeNewswire: 2024-09-08 19:10:00

MacroGenics, Inc. announced Phase 2 data of vobramitamab duocarmazine in mCRPC at ESMO Congress in Barcelona from Sept. 13-17, 2024. The poster by Dr. Johann de Bono will report data from a July 9, 2024, cut-off, including updated safety and efficacy data on rPFS. A conference call on Sept. 16 at 8:00 a.m. ET will further discuss the TAMARACK poster data and offer a general update. MacroGenics focuses on antibody-based cancer therapeutics and collaborates globally. Any forward-looking statements should be viewed as the Company’s current perspective and subject to change with evolving events.



Read more at GlobeNewswire: MacroGenics Announces TAMARACK Phase 2 Data Presentation at